Compare TG Therapeutics Inc (TGTX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Energy Select Sector SPDR Fund — how do they compare? TG Therapeutics Inc trades at $55.24 (market cap $8.16B), while Energy Select Sector SPDR Fund trades at $65.14 (market cap $40.84B). The key difference: Energy Select Sector SPDR Fund is far larger — about 5× TG Therapeutics Inc's market cap, and Energy Select Sector SPDR Fund is more actively traded (50,409,268 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| TGTX | XLE | |
|---|---|---|
Market Cap | $8.16B | $40.84B |
Volume | 1,735,121 | 50,409,268 |
Sector | Health | — |
52-Week High | $59.06 | $65.93 |
52-Week Low | $26.94 | $42.61 |
Typical Hold Time | 16 Days | 67 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
XLE trades at $65.27, up 2.98% on the day, with a bullish technical signal from moving averages but caution from oscillators like the RSI at 70.16. The ETF, heavily concentrated in oil and gas, benefits from rising oil prices above $100 amid Middle East tensions and supply constraints. Recent news highlights strategic oil reserve releases and diesel price pressures, influencing energy sector volatility.
Outlook remains tied to oil price dynamics, with upside from sustained geopolitical risks but downside if crude reverses. Risks include oil market volatility and potential Fed rate hikes. Analyst sentiment is mixed, balancing energy sector strength against overbought technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
